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Abstract
Dysregulation of nitric oxide (NO) and increased oxidative and nitrosative stress are implicated in
the pathogenesis of heart failure. Peroxynitrite is a reactive oxidant that is produced from the reaction
of nitric oxide with superoxide anion and impairs cardiovascular function through multiple
mechanisms, including activation of matrix metalloproteinases (MMPs) and nuclear enzyme poly
(ADP-ribose) polymerase (PARP). Recent studies suggest that the neutralization of peroxynitrite or
pharmacological inhibition of MMPs and PARP are promising new approaches in the experimental
therapy of various forms of myocardial injury. In this article, the role of nitrosative stress and
downstream mechanisms, including activation of MMPs and PARP, in various forms of heart failure
are discussed and novel emerging therapeutic strategies offered by neutralization of peroxynitrite
and inhibition of MMPs and PARP in these pathophysiological conditions are reviewed.
Role of increased oxidative stress in heart failure
Acute heart failure and chronic heart failure (CHF) are major causes of hospitalization,
morbidity and mortality worldwide. Several different mechanisms can lead to cardiac pump
failure (Figure 1). These mechanisms result in a mismatch between the load applied to the heart
and the energy needed for contraction, which leads to reduced contractile efficiency (Figure
1).
The pathomechanism of heart failure is complex and involves the activation of numerous
secondary pathways (e.g. pathways involving neurohormones, cytokines, oxidative stress and
nitrosative stress), which leads to: (i) abnormalities in various signaling processes, cardiac
receptors and Ca2+ homeostasis; (ii) contractile protein desensitization; and (iii) endothelial
dysfunction. The resulting structural alterations can involve cardiac and vascular remodeling
with hypertrophy, fibrosis, cardiac dilation and myocardial necrosis. The adverse remodeling
and increased peripheral resistance further aggravate heart failure (Figure 1).
Experimental and clinical studies demonstrate increased production of reactive oxygen species
(ROS) in the pathogenesis of acute heart failure and CHF. Plasma malondialdehyde-like
activity (MDA), a marker of lipid peroxidation, is increased in patients with ischemic and non-
ischemic dilated cardiomyopathy, and has an inverse relationship with ejection fraction (an
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index of cardiac function) and exercise capacity. The pericardial concentration of 8-iso-
prostaglandin F2 (a marker for ROS production) in these patients also correlates closely with
the degree of contractile dysfunction (reviewed in [1]).
The generation of ROS in the myocardium is triggered by ischemia and reperfusion and by
exposure of the heart to inflammatory cytokines [e.g. tumor necrosis factor α (TNF-α) and
interleukin 6 (IL-6)]. Impaired antioxidant defense mechanisms (superoxide dismutase,
catalase and glutathione peroxidase) or reduced concentrations of endogenous antioxidants
(vitamin E, ascorbic acid and glutathione) can also increase ROS levels within the myocardium.
Sources of ROS in failing myocardium include, among many others, xanthine and NAD(P)H
oxidoreductases, the mitochondrial electron transport chain and activated neutrophils [1–4].
Role of increased nitrosative stress and dysregulation of nitric oxide
synthase in heart failure
Cardiomyocytes, endocardial endothelium, coronary endothelium and cardiac nerves are all
sources of nitric oxide (NO) produced by Ca2+-dependent NO synthase (NOS) enzymes. NO
serves several important physiological roles in the regulation of cardiac function, including
coronary vasodilatation, inhibition of platelet and neutrophil adhesion and activation,
modulation of cardiac contractile function, and inhibition of cardiac oxygen consumption
(reviewed in [4–6]).
NO is necessary for normal cardiac physiology and has a protective role in the ischemic heart.
This protective role is mediated by several mechanisms, including the stimulation of soluble
guanylyl cyclase, which leads to a decrease of the concentration of intracellular Ca2+, and the
termination of chain-propagating lipid radical reactions caused by oxidative stress [7].
However, reactive nitrogen species can also exert cytotoxic effects. Many of the toxic actions
of NO are not due directly to NO itself but are mediated by the highly reactive oxidant
peroxynitrite, which is produced following interaction of NO with superoxide anions (reviewed
in [8,9]) (Table 1).
NO is overproduced in the failing myocardium as a result of the increased expression and
activity of the inducible isoform of NOS (iNOS) [9,10]. There is a correlation between
myocardium-specific, chronic over-expression of iNOS and peroxynitrite generation and
cardiac enlargement, conduction defects, sudden cardiac death and, less commonly, heart
failure (HF) in mice [11]. Myocardial iNOS is induced in rats that have volume-overload HF,
and increased iNOS activity in these rats leads to: (i) a loss of myocardial contractility; and (ii)
β-adrenoceptor hyporesponsiveness [12]. NO derived from neuronal NOS is also present in
the failing human heart [13]. It is likely that it is not the net amount of NO produced per se
that determines cardiac cytotoxicity, but instead the type of reactive nitrogen species present
(e.g. the toxic oxidant peroxynitrite produced following the interaction of NO and superoxide)
[8,9,14]. The generation of peroxynitrite has been demonstrated in various forms of acute heart
failure and CHF in both animals and humans (Table 2) [11,15–30].
CHF is also characterized by impaired endothelium-dependent vasodilatation, which might
contribute to increased peripheral vascular resistance. The pathogenesis of endothelial
dysfunction associated with CHF involves enhanced oxidative stress from various local
sources. A potential additional source of ROS is iNOS, which, paradoxically, can produce
superoxide instead of NO if L-arginine (from which NO is normally produced) is depleted or
there is a lack of the important cofactor tetrahydrobiopterin (BH4). The importance of this
mechanism has been demonstrated in cultured cells, and in vascular tissues from CHF animals
or humans [31,32], but has not yet been studied in hearts from CHF animals or patients.
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Mechanisms of peroxynitrite-induced cardiac and vascular dysfunction
There are multiple possible downstream targets of peroxynitrite (Table 1, Figure 2) (reviewed
in [8,9,14]). For example, peroxynitrite-induced tyrosine nitration can lead to dysfunctional
nitrated proteins whereas peroxynitrite-induced oxidation of crucial sulfydryl groups can
inhibit important enzymes in the mitochondrial respiratory chain. Indeed, peroxynitrite-
mediated nitration of myofibrillar creatine kinase impairs myocardial contractility [10].
Furthermore, peroxynitrite-modified cellular proteins are subject to accelerated degradation
via the proteasome and peroxynitrite inhibits a variety of ion pumps, including Ca2+ pumps,
Ca2+-activated K+ channels and Na+–K+-ATPase [8,9].
Peroxynitrite also potently oxidizes various biomolecules including BH4, a crucial cofactor of
NOS, to quinonoid 5,6-dihydrobiopterin. A large proportion of the quinonoid isomer readily
loses its side-chain to form 7,8-dihydropterin, which does not serve as a cofactor for NOS.
Low cellular levels of BH4 can promote a cycle of its own destruction mediated by NOS-
dependent formation of peroxynitrite. This mechanism might contribute to vascular endothelial
dysfunction. The generation of peroxynitrite also decreases the availability of NO for G-protein
stimulation and vasodilatation, thus further contributing to endothelial dysfunction. In addition,
peroxynitrite can inhibit superoxide dismutase, glutaredoxin and other antioxidant molecules
and systems, which leads to positive feedback cycles of intracellular oxidant generation and
oxidative injury [8,9]. As overviewed in subsequent sections, peroxynitrite can also activate
matrix metalloproteinases (MMPs) [33,34] and the nuclear enzyme poly(ADP-ribose)
polymerase (PARP) [8,35] in HF. Peroxynitrite also triggers the expression of P-selectin,
intercellular adhesion molecule 1 (ICAM-1) and Mac-1 (CD11b/CD18), and mediates the
cytokine-induced expression of IL-8 in human leukocytes via enhancement of nuclear factor
κB (NF-κB) activation [8], thereby promoting pro-inflammatory responses.
Role of peroxynitrite-induced activation of matrix metalloproteinases
MMPs are a family of proteolytic enzymes that are best known for their ability to degrade and
remodel the extracellular matrix. MMPs are now also recognized to have a variety of novel
actions as proteases on substrates other than extracellular matrix proteins. They have important
roles both under physiological (e.g. angiogenesis and remodeling of the endometrium) and
pathophysiological (e.g. neutrophil infiltration, cancer cell invasion and connective tissue
remodeling) conditions. In the heart, collagens are the major extracellular matrix proteins that
surround and interconnect myocytes and muscular fibers to provide mechanical support. Loss
of collagen leads to myocyte slippage, ventricular dilation, and progressive contractile
dysfunction. Importantly, modulation of the balance between the synthesis and degradation of
matrix proteins is implicated in the process of ventricular remodeling during CHF (reviewed
in [34,36]). The type of MMP involved is important. For example, changes in gelatinases
(MMP-2 and MMP-9) are not directly involved in fibrillar collagen breakdown or the cardiac
remodeling produced by catabolism of type I and III collagens, whereas MMP-1 (interstitial
collagenase), MMP-8 (neutrophilcollagenase),MMP-13(collagenasetype3)and MMP-14
[MT1 (membrane type 1)-MMP] are the only MMPs that cleave triple helical collagen [37].
MMPs are thought to be secreted in an inactive form from cells and activated at the cell
membrane via a proteolytic mechanism. However, this paradigm of only extracellular
activation and action of MMPs, particularly that of MMP-2, has been challenged by recent
evidence.
Increased oxidative and nitrosative stress have been proposed to have an important role in the
activation of MMPs both in vitro and in vivo (reviewed in [34,36,37]). Oxidative stress causes
tissue injury through activation of pro-MMPs, which is triggered by the interaction of
peroxynitrite with cytosolic glutathione and subsequent S-glutathiolation of a crucial cysteine
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residue in the autoinhibitory domain of the pro-MMP, resulting in a catalytically active pro-
MMP [33]. MMP-2 is activated and released from the reperfused heart following ischemia,
and inhibition of MMP-2 activity functionally protects the heart from ischemia–reperfusion
injury [38]. Infusion of peroxynitrite into isolated rat hearts results in MMP-2 activation, which
precedes the onset of mechanical dysfunction, an effect that is abolished by MMP inhibitors
[39]. Upon ischemia–reperfusion injury MMP-2 was found to be localized to the sarcomeric
thin myofilaments and was responsible for the proteolytic cleavage of troponin I [40], which
contributes to the early reduction of myocardial contractility in acute myocardial reperfusion
injury.
MMP-2 activity is increased in the myocardium of spontaneously hypertensive rats with CHF
and correlates with ventricular dilation and age-dependent dysfunction. Inhibition of MMP-2
activity ameliorates these changes [41]. Targeted deletion of MMP-9 also attenuates left
ventricular remodeling after experimental myocardial infarction in mice [42]. Additional
evidence for the importance of MMP-2 and -9 in the heart is provided by the demonstration
that, in a porcine model, MMP inhibitors ameliorate ventricular dysfunction induced by rapid
ventricular pacing [43]. Peroxynitrite-dependent early activation of MMP-2 also occurs in rat
hearts exposed to pro-inflammatory cytokines [26] and in a doxorubicin-induced murine heart
failure model [15,16]. Contractile failure of the heart was reduced either by MMPs inhibitors
[26] or by a peroxynitrite decomposition catalyst [15,16].
MMP-2 and MMP-9 have pivotal roles in a variety of human cardiovascular disorders. The
activities of both these MMPs are increased in the ventricles of patients suffering from dilated
cardiomyopathy [44] and in atrial biopsies of patients undergoing cardiopulmonary bypass
[45]. The concentration of plasma MMP-9 might predict adverse cardiovascular events [46].
Furthermore, a particular polymorphism of MMP-9 (R279Q) is highly associated with the
occurrence of stable angina in humans [46].
Role of poly(ADP-ribose) polymerase (PARP) activation
Poly(ADP-ribose) polymerase 1 (PARP-1) is the major isoform of a family of nuclear enzymes
with multiple regulatory functions. PARP cleaves NAD+to nicotinamide and ADP-ribose to
form long branches of ADP-ribose polymers on nuclear target proteins. PARP activation exerts
its pathophysiological effects via two principal mechanisms (reviewed in [35]). First, when
PARP is activated by single-strand breaks in DNA, it catalyzes the cleavage of NAD+ into
nicotinamide. As a result, in oxidatively or nitrosatively stressed cells NAD becomes depleted,
impairing glycolysis, Krebs cycle and mitochondrial electron transport, eventually resulting in
ATP depletion. Second, PARP-1 regulates the expression of various proteins, including iNOS,
ICAM-1, and various cytokines and chemokines, at the transcriptional level. Pharmacological
inhibition or genetic deletion of PARP attenuates the production of a variety of inflammatory
mediators in vivo [35]. The relative contribution of the two mechanisms to acute heart failure
and CHF has not yet been clarified completely. In acute hypoxic-reoxygenated hearts, there is
a massive drop in NAD and ATP levels, compared with in control hearts, and PARP inhibitors
accelerate the recovery of these energetic pools during reperfusion [47]. The effect of PARP
inhibitors on myocardial energetics in CHF has not yet been studied. The triggers of PARP
activation, in general, are DNA strand breakage and increased intracellular concentrations of
Ca2+ [35]; both of these triggers have been demonstrated in acute heart failure and CHF [1,
48,49].
Pharmacological inhibition or genetic deletion of PARP markedly improves the outcome of
myocardial ischemia–reperfusion injury [35,48] and various forms of cardiomyopathy and
CHF (Table 3) [15,21,50–68]. In diabetic cardiomyopathy models the depression of myocardial
contractile function was associated with a significant increase in poly(ADP-ribosyl)ation in
Pacher et al. Page 4
Trends Pharmacol Sci. Author manuscript; available in PMC 2008 February 4.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
cardiac myocytes [54]. In rat models of CHF induced by chronic coronary artery ligation and
advanced aging, increased nitrosative stress and poly(ADP-ribosyl)ation were found in both
myocytes and endothelial cells. Pharmacological inhibition of PARP attenuated the myocardial
hypertrophy and improved endothelial function in these rat models [21,62]. Using a dual
approach of PARP-1 suppression by genetic deletion or pharmacological inhibition, the role
of oxidative and nitrosative stress-induced PARP activation in the development of cardiac
dysfunction induced by doxorubicin was also demonstrated [15,52,69]. Most recently, two
studies demonstrated increased poly(ADP-ribosyl)ation and overexpression of PARP-1 in the
myocardium of mice with aortic banding-induced CHF [49,53]. In these studies inhibition or
genetic inactivation of PARP protected against a hypertrophy response and heart failure
induced by aortic banding. There is also evidence for overexpression of PARP-1 in biopsies
from human subjects with CHF [49]. Pharmacological inhibition of PARP or genetic PARP-1
deficiency also prevents the mitochondrial-to-nuclear translocation of the cell death factor
apoptosis-inducing factor (AIF) in a banding-induced murine heart failure model [53].
Angiotensin II might also be important in PARP activation and the pathogenesis of heart failure.
Angiotensin II is a known factor in the pathogenesis of CHF, and can induce endothelial
peroxynitrite formation [70] and PARP activation [58]. Angiotensin II triggers the activation
of PARP in cultured endothelial cells in vitro and chronic infusion of sub-pressor doses of
angiotensin II triggers endothelial dysfunction in vivo, which can be prevented or reversed by
PARP inhibition [58]. A recent study also implicates PARP in regulating the expression of
endothelin receptors [71], and the dysregulation of endothelin signaling is known to be
important in CHF.
Although the exact molecular triggers of PARP activation in CHF are unknown, we propose
that following initial damage (e.g. myocardial infarction) the compensatory increased
sympathetic activity, activated renin–angiotensin system and increased workload of the non-
infarcted regions of the myocardium leads to myocardial hypertrophy, myocardial ischemia or
functional hypoxia, increased oxidative and nitrosative stress and PARP activation, which in
turn results in alterations in cellular energetics and the activation of pro-inflammatory pathways
(Figures 1 and 2).
Possibilities for future pharmacological interventions for the experimental
therapy of heart failure
Although there is strong experimental evidence for the role of ROS and reactive nitrogen
species in the development of the structural and functional changes of the failing myocardium,
the results of clinical trials with antioxidants such as vitamin C, vitamin E and coenzyme Q10
are equivocal [1]. The reason for these findings might be related to the type of antioxidant used
(relatively low reaction rate with the reactive species or non-catalytic antioxidant) and the dose
of the antioxidant used (less than the doses used in preclinical animal studies).
Approaches that use more-effective antioxidants (catalytic antioxidants with high reaction
rates) or that specifically target myocardial oxidant-producing enzymes or specific downstream
targets of oxidative or nitrosative stress might be more fruitful approaches in the future. For
example, xanthine oxidase, which is an important source of superoxide in the failing heart, can
be inhibited by pharmacological agents (e.g. allopurinol and oxypurinol). Both preclinical and
clinical studies demonstrate that this approach improves cardiac efficiency and might become
a future therapeutic modality. Furthermore, the data obtained so far in short-term clinical
studies with allopurinol in CHF patients are encouraging (reviewed in [3]). In theory,
mitochondrial uncoupling proteins might reduce superoxide formation in mitochondria in the
heart [72], but such an approach might induce several unwanted effects. The pathogenetic role
of NADPH oxidase in CHF might be exploited with apocynin (a weak nonselective NADPH
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oxidase inhibitor) [73] or with yet to be identified more-potent or more-selective NADPH
oxidase inhibitors.
Peroxynitrite decomposition catalysts appear to improve cardiac function and overall outcome
in animal models of CHF. For example, the metalloporphyrin peroxynitrite decomposition
catalyst FP15 reduced myocardial necrosis in rat [15] and pig [68] models of acute myocardial
infarction, and improved mechanical dysfunction in rat hearts exposed to pro-inflammatory
cytokines [74]. Furthermore, catalytic decomposition of peroxynitrite significantly improved
cardiac function in models of diabetic and doxorubicin-induced cardiomyopathy [15,55,75].
Both ROS and reactive nitrogen species trigger downstream cellular suicide pathways. As
discussed earlier, MMP activation and PARP activation might be two examples of such
pathways, and in both cases there are significant preclinical data demonstrating their efficacy
in HF models (see earlier and Table 3). With respect to MMP inhibitors, there are several
compounds (including the tetracycline-class antibiotics, which possess the ability to inhibit
MMP activity independently of their antibacterial action [38]) that might be used clinically
and might be suitable for controlled clinical investigations. In fact, recent preclinical studies
demonstrate the cardioprotective effects of doxycycline in myocardial infarction [76,77], and
in a small clinical trial a sub-antimicrobial dose of doxycycline (the most potent tetracycline
inhibitor of MMP) attenuated the levels of several inflammatory markers in post-myocardial
infarction patients [78]. In addition, potent pharmacological PARP inhibitors have recently
undergone clinical investigations for cardioprotective indications [79].
It must be kept in mind that, at present, CHF patients receive a variety of therapeutic agents,
some of which have known antioxidant effects (e.g. the β-adrenoceptor antagonist carvedilol).
In the case of diabetic heart failure, it must also be kept in mind that acute (in addition to
chronic) hyperglycemia are strong triggers of ROS and reactive nitrogen species formation in
the cardiovascular system [75,80]. Therefore, tight control of hyperglycemia in diabetics might
be one of the best ways to prevent the production of reactive species and the initiation of
downstream pathways of myocardial injury. Whether conventional interventions (e.g.
antioxidant therapies, statins, β-adrenoceptor antagonists, angiotensin-converting enzyme
inhibitors, insulin or oral anti-diabetic agents) are able to suppress the activation of PARP or
MMPs during CHF remains to be investigated. Overall, we expect that recent advances in our
understanding of the role of reactive species in the pathogenesis of heart failure will, in the
not-so-distant future, yield novel therapeutic approaches (monotherapy or combination
approaches) that will be exploited for the benefit of patients with heart failure.
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Figure 1.
Progression of heart failure and the role of oxidative and nitrosative stress. The mechanisms
that lead to heart failure are of multiple origins and include acute and chronic ischemic heart
disease, cardiomyopathies, myocarditis and pressure overload. These diseases result in a
mismatch between the load applied to the heart and the energy needed for contraction, leading
to mechanoenergic uncoupling. Following initial insult, secondary mediators such as
angiotensin II (Ang II), noradrenaline (NA), endothelin (ET) and pro-inflammatory cytokines
[e.g. tumor necrosis factor α (TNF-α) and interleukin 6 (IL-6)], in concert with oxidative and
nitrosative stress, act directly on the myocardium or indirectly via changes in hemodynamic
loading conditions to cause endothelial and myocardial dysfunction, cardiac and vascular
remodeling with hypertrophy, fibrosis, cardiac dilation and myocardial necrosis, leading
eventually to heart failure. The adverse remodeling and increased peripheral resistance further
aggravate heart failure. Abbreviations: MMP, matrix metalloproteinase; PARP, poly(ADP-
ribose) polymerase.
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Figure 2.
Proposed role of the oxidative and nitrosative stress–poly(ADP-ribose) polymerase 1
(PARP-1) pathway in oxidant-induced cellular dysfunction and necrosis. Nitric oxide (NO)
and superoxide ( O2‐ ) (derived from NADPH oxidase, mitochondria, xanthine oxidase and
catechol oxidation) react to form peroxynitrite (ONOO−), which induces cell damage via lipid
peroxidation, inactivation of enzymes and other proteins by oxidation and nitration, and
activation of matrix metalloproteinases (MMPs) among others (a) (Table 1). Peroxynitrite also
acts on mitochondria [decreasing the membrane potential (Ψ)], triggering the release of pro-
apoptotic factors such as cytochrome c (Cyt c) and apoptosis-inducing factor (AIF) (b). These
factors mediate caspase-dependent and caspase-independent apoptotic death pathways,
respectively. Moreover, peroxynitrite, in concert with other oxidants [e.g. hydrogen peroxide
(H2O2)], causes strand breaks in DNA, activating PARP-1 (c). Mild damage to DNA activates
the DNA repair machinery. By contrast, once excessive oxidative and nitrosative stress-
induced DNA damage occurs, as in various forms of myocardial reperfusion injury and heart
failure, overactivated PARP-1 initiates an energy-consuming cycle by transferring ADP-ribose
units (small orange spheres) from NAD+ to nuclear proteins, resulting in rapid depletion of the
intracellular NAD+ and ATP pools, slowing the rate of glycolysis and mitochondrial
respiration, and eventually leading to cellular dysfunction and death. Poly (ADP-ribose)
glycohydrolase (PARG) degrades poly(ADP-ribose) (PAR) polymers, generating free PAR
polymer and ADP-ribose. PARP-1 also regulates the expression of a variety of inflammatory
mediators, which might facilitate the progression of heart failure.
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Table 1
Cytotoxic processes initiated by peroxynitrite in vitro
Action Mechanism(s)
Lipid peroxidation Peroxidation
Inhibition and depletion of antioxidant enzymes Oxidation and nitration of glutathione and cysteine (required by antioxidant enzymes)
Activation of matrix metalloproteinases (MMPs) S-Glutathiolation of pro-matrix metalloproteinases
Disturbances of signal transduction pathways Oxidation and nitration of various proteins
Mitochondrial dysfunction Inhibition of, for example, cytochromes and NADH-CoQ1 reductase (complex I)
Inhibition of cytosolic enzymes and membrane pumps Oxidation and nitration of various proteins
Ca2+ dysregulation Inhibition of ion pumps (e.g. Ca2+ pumps, Ca2+-activated K+ channels and Na+–K+-ATPase,
leading to dysfunctional cell energetics
Contractile protein dysfunction Oxidation and nitration of contractile proteins
Upregulation of adhesion receptors Activation of NF-κB
DNA injury and PARP activation Oxidation and nitration of various proteins
Inhibition of NAD-dependent enzymes NAD oxidation, and NAD depletion via PARP
Apoptosis Mitochondrial injury, DNA injury, caspase activation, signal transduction disturbances and
Ca2+ dysregulation
Cell necrosis Mitochondrial injury, energetic collapse, oxidation, nitration, antioxidant depletion and
Ca2+ dysregulation
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Table 2
Evidence for nitrosative stress and peroxynitrite in various forms of cardiac injurya
Experimental model Disease or trigger Main findings Refs
Mouse Chronic myocardial ischemia Increased myocardial iNOS expression, plasma nitrate
and nitrite concentrations, and myocardial and plasma
nitrotyrosine levels in wild-type compared with iNOS−/−
mice; improved left ventricular function in iNOS−/− mice
compared with wild-type mice
b
Mouse Cardiac-
specific iNOS overexpression
Increased peroxynitrite production, inflammation, cardiac
fibrosis, hypertrophy, dilatation and sudden cardiac death
compared with wild-type mice
[11]
Mouse Doxorubicin Increased myocardial iNOS expression, nitrotyrosine
formation and matrix metalloproteinase activation, which
correlates with cardiac dysfunction
[15,16]b
Mouse LPBM5 retrovirus (murine AIDS
model)
Progressive cardiac dysfunction correlated with increased
myocardial inflammation and protein nitration
[17]
Mouse, rat heart High glucose, STZ-induced diabetes Increased levels of apoptosis, hydrogen peroxide,
superoxide, angiotensin II, NO and nitrotyrosine
formation and increased iNOS expression in myocytes
[18]b
Rat cardiac myofibrils,
trabeculae
Peroxynitrite Concentration-dependent nitration of myofibrillar
creatine kinase; decreased activity of creatine kinase and
impaired contractile force generation
[19,20]b
Rat Chronic myocardial ischemia Increased myocardial nitrotyrosine formation and
decreased myofibrillar creatine kinase activity
[21]b
Rat heart Global ischemia– reperfusion Cardiac dysfunction; decreased efficiency of oxygen
utilization and ATP and membrane-bound creatine kinase
activity; increased iNOS expression; increased formation
of superoxide and myocardial peroxynitrite; NOS
inhibition, superoxide dismutase and urate (a
peroxynitrite scavenger) greatly enhanced the recovery of
contractile function in post-ischemic hearts
[22]b
Rat heart Endotoxin Enhanced generation of NO, superoxide and peroxynitrite
in dysfunctional hearts from endotoxemic rats
[23,24]
Rat, mouse Porcine cardiac myosin Autoimmune myocarditis characterized by myocardial
destruction, inflammation and increased iNOS expression
and nitrotyrosine formation, which is decreased by the
iNOS inhibitor aminoguanidine
b
Rat heart, rat cardiac
myocytes
Mixture of pro- inflammatory
cytokines
Increased production of superoxide and NO, increased
peroxynitrite formation and increased activation of matrix
metalloproteinase 2 (MMP-2); contractile dysfunction,
which is prevented by superoxide and peroxynitrite
scavengers, an MMP-2 antibody or MMP inhibitors
[25,26]b
Dog Pacing, intracoronary inflammatory
cytokine
Cardiac dysfunction, nitrotyrosine formation and cell
death in myocytes, which is prevented by the iNOS
inhibitor aminoguanidine or a superoxide scavenger
b
Dog, pig Regional ischemia– reperfusion Increased nitrotyrosine formation and cardiac dysfunction [27]b
Human Coronary artery disease, atrial
fibrillation, cardiopulmonary bypass
surgery
Increased NOS activity and nitrotyrosine formation in
myocytes of patients
[28–30]
b
Human Type 2 diabetes mellitus,
hypertension
Increased apoptosis, necrosis and formation of
angiotensin II and nitrotyrosine in myocytes
b
Human HIV Increased myocardial nitrotyrosine formation in patients
with HIV-induced dilated cardiomyopathy
[17]
a
Abbreviations: iNOS, inducible nitric oxide synthase; NO, nitric oxide; STZ, streptozotocin.
b
Studies published before 2002 are not included in the reference list, but are reviewed in [9,14].
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Table 3
Protection against cardiac dysfunction and injury by scavenging of peroxynitrite or by inhibition of PARPa
Experimental model Trigger of injury Mode of peroxynitrite
neutralization or PARP
inhibitionb
Effects of peroxynitrite
neutralization or PARP
inhibition
Refs
Mouse, mouse heart Global or regional ischemia–
reperfusion
PARP−/− phenotype Improved left ventricular function;
reduced myocardial damage and
apoptosis; reduced neutrophil
infiltration; reduced circulating
TNF-α, IL-10, nitrate, ICAM-1 and
P-selectin expression, NAD+
consumption, NF-κB activation
and phosphorylative activity of
JNK and AP-1 activation;
increased HSF-1 and HSP70
activation
[50,
51]c
Mouse Doxorubicin PARP−/− phenotype,
PJ34, FP15
Improved contractile function;
reduced myocyte death; decreased
mortality
[15,
52]
Mouse Aortic banding PARP−/− phenotype,
INO1001
Decreased hypertrophy and
improved contractile function;
improved survival
[49,
53]
Mouse, rat NOD diabetes, STZ diabetes,
regional ischemia–reperfusion
PJ34, FP15, INO1001 Improved cardiac and vascular
function; reduced infarct size and
mitochondrial-to-nuclear
translocation of the cell death
effector apoptosis- inducing factor
(AIF) in myocardial infarction
[54–
56]
Mouse, rat Endotoxin PARP−/− phenotype,
PJ34
Improved contractile function and
decreased mortality
[57]
Mouse, rat Angiotensin II infusion PJ34, INO1001 Improved endothelial function [58]
Rat cardiomyoblasts,
rat and human
cardiomyocytes
Hydrogen peroxide,
peroxynitrite, hypoxia
reoxygenation
3-AB, nicotinamide, 5-
AIQ
Reduced cell death; improved
mitochondrial respiration and
cellular ATP levels
c
Rat heart Mixture of pro- inflammatory
cytokines
Tiron, FeTPPS Improved cardiac function in
cytokine-induced myocardial
contractile failure
c
Rat, rat and rabbit
heart
Regional and global ischemia–
reperfusion
FP15, 3-AB,
nicotinamide, 5-AIQ,
BGP15, GPI6150
Reduction of infarct size and left
ventricular dysfunction;
preservation of myocardial ATP
stores
[15,
22]c
Rat Heart transplantation 3-AB, PJ34, 5-AIQ Decreased myocardial damage;
reduced oxidative stress; improved
cellular NAD+ and ATP levels;
improved contractile and
endothelial function; reduced
ICAM-1 and P-selectin expression
[59–
61]
Rat Chronic myocardial ischemia
and advanced aging
PJ34, INO1001 Improved left ventricular and
vascular function; reduced
hypertrophy
[21,
62]
Rat Endotoxin iNOS inhibitor
mercaptoethylguanidine
and peroxynitrite
decomposition catalyst
FeTPPS
Improved contractile function and
decreased myocardial peroxynitrite
accumulation; decreased
degradation of the NF-κB
inhibitory protein IκB; decreased
levels of plasma TNF-α; decreased
vascular endothelial cell–leukocyte
activation
[63]
Rat heart High glucose M40403 Decreased QT interval
prolongation; decreased coronary
perfusion pressure and lipid
peroxidation; decreased
nitrotyrosine formation and PARP
activation
[64]
Dog Cardiopulmonary bypass;
crystalloid cardioplegia and
extra-corporal circulation
PJ34, INO1001 Better recovery of left and right
ventricular systolic function;
increased coronary blood flow;
improved vascular and pulmonary
function
[65–
67]
Pig Regional ischemia– reperfusion FP15, 3-AB, PJ34 Reduced infarct size; improved left
ventricular function
[68]
c
a
Abbreviations: AP-1, activator protein 1; HSF-1, heat shock transcription factor 1; HSP70, heat shock protein 70; ICAM-1, intercellular adhesion molecule
1; IL-10, interleukin 10; iNOS, inducible nitric oxide synthase; JNK, Jun N-terminal kinase; NF-κB, nuclear factor κB; NOD, non-obese diabetic; PARP,
poly(ADP-ribose) polymerase; STZ, streptozotocin; TNF-α, tumor necrosis factor α.
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b
The following drugs were used in these studies: (i) early PARP inhibitors of low potency [3-aminobenzamide (3-AB) and nicotinamide]; (ii) a potent
new generation of selective PARP inhibitors {e.g. GPI6150 (1,11b-dihydro-[2H]benzopyrano[4,3,2-de]isoquinolin-3-one), BGP15 (O-(3-piperidino-2-
hydroxy-1-propyl)nicotinic amidoxime), 5-AIQ (5-aminoisoquinolinone), PJ34 (N-(6-oxo-5,6-dihydro-phenanthridin-2-yl)-N,N-dimethylacetamide
HCl) and INO1001 (isoindolinone-based PARP inhibitor)}; (iii) antioxidants (tiron); (iv) peroxynitrite decomposition catalysts {FeTPPS [5,10,15,20-
tetrakis(4-sulfonatophenyl)porphyrinato iron (III)], FP15 [FeCl tetrakis-2-(triethylene glycol monomethyl ether) pyridyl porphyrin]}; and (v) the
superoxide dismutase (SOD) mimetic M40403 [a manganese (II) complex with a bis(cyclohexylpyridine-substituted) macrocyclic ligand].
c
Studies published before 2002 are not included in the reference list, but are reviewed in [35,48].
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